Stay updated on Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T08:17:54.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, blocking access to the study record content and replacing the usual page with a site-wide error message.
    Difference
    0.5%
    Check dated 2026-09-27T06:59:40.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The page pruned the Study Documents area, removing items like the Study Protocol and Statistical Analysis Plan, along with investigator names and historical submission details. This narrows access to essential study documentation and historical context within the record.
    Difference
    19%
    Check dated 2026-09-20T02:24:29.000Z thumbnail image
  5. Check
    49 days ago
    Change Detected
    Summary
    A new Revision tag shows v3.6.6, replacing v3.6.5, indicating a platform update. It represents an internal software version change rather than a modification to the study content or user-facing information.
    Difference
    0.1%
    Check dated 2026-08-29T23:41:52.000Z thumbnail image
  6. Check
    70 days ago
    Change Detected
    Summary
    The revision tag in the page footer was updated from v3.6.4 to v3.6.5, indicating a newer version of the page. This change updates the page metadata without affecting the study details, layout, or user interactions.
    Difference
    0.1%
    Check dated 2026-08-08T23:25:26.000Z thumbnail image
  7. Check
    84 days ago
    Change Detected
    Summary
    The page now shows a new revision tag indicating a software update (from v3.6.3 to v3.6.4); this reflects a backend change and does not alter the study details or user-visible information.
    Difference
    0.1%
    Check dated 2026-07-25T17:45:58.000Z thumbnail image

Stay in the know with updates to Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.